The Kyoto Prognostic Index for patients with diffuse large B-cell lymphoma in the rituximab era

被引：0
|
作者：
T Kobayashi
J Kuroda
I Yokota
K Tanba
T Fujino
S Kuwahara
R Isa
J Yamaguchi
E Kawata
T Akaogi
H Uchiyama
H Kaneko
N Uoshima
Y Kobayashi
S Teramukai
M Taniwaki
机构：
[1] Kyoto Prefectural University of Medicine,Division of Hematology and Oncology, Department of Medicine
[2] Graduate School of Medical Science,Department of Biostatistics
[3] Kyoto Prefectural University of Medicine,Department of Hematology
[4] Japanese Red Cross Kyoto Daini Hospital,Department of Hematology
[5] Japanese Red Cross Kyoto Daiichi Hospital,Department of Hematology
[6] Aiseikai Yamashina Hospital,undefined
来源：
Blood Cancer Journal | 2016年 / 6卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：e383 / e383
相关论文
共 50 条
  • [21] Outcomes of Cardiac Diffuse Large B-Cell Lymphoma in the Rituximab Era
    Al-Juhaishi, Taha
    Abu Zeinah, Ghaith
    Al-Kindi, Sadeer
    BLOOD, 2020, 136
  • [22] Primary breast diffuse large B-cell lymphoma in the era of rituximab
    Zhang, Na
    Cao, Caineng
    Zhu, Yuan
    Liu, Peng
    Liu, Luying
    Lu, Ke
    Luo, Jialin
    Zhou, Ning
    ONCOTARGETS AND THERAPY, 2016, 9 : 6093 - 6097
  • [23] Rebirth of radiotherapy for elderly patients with diffuse large B-cell lymphoma in the rituximab era
    Flowers, Christopher R.
    Cohen, Jonathon B.
    Khan, Mohammad K.
    LEUKEMIA & LYMPHOMA, 2015, 56 (03) : 557 - 558
  • [24] THE HIGHEST PROGNOSTIC IMPACT OF LDH AMONG INTERNATIONAL PROGNOSTIC INDICES IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA IN THE RITUXIMAB ERA
    Park, J. H.
    Suh, C.
    Yoon, D. H.
    Kim, S. M.
    Kim, D. Y.
    Kim, S.
    Kim, J.
    Kim, K. A.
    Lee, S. W.
    Park, C.
    Huh, J.
    HAEMATOLOGICA, 2012, 97 : 128 - 128
  • [25] Statin Use and Prognosis in Patients With Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in the Rituximab Era
    Nowakowski, Grzegorz S.
    Maurer, Matthew J.
    Habermann, Thomas M.
    Ansell, Stephen M.
    Macon, William R.
    Ristow, Kay M.
    Allmer, Cristine
    Slager, Susan L.
    Witzig, Thomas E.
    Cerhan, James R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (03) : 412 - 417
  • [26] PHARMACOKINETICS OF RITUXIMAB IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA
    Rozman, S.
    Grabnar, I.
    Novakovic, S.
    Mrhar, A.
    Novakovic, B. Jezersek
    HAEMATOLOGICA, 2017, 102 : 688 - 688
  • [27] Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story
    Bari, A.
    Marcheselli, L.
    Sacchi, S.
    Marcheselli, R.
    Pozzi, S.
    Ferri, P.
    Balleari, E.
    Musto, P.
    Neri, S.
    Spiriti, M. A. Aloe
    Cox, M. C.
    ANNALS OF ONCOLOGY, 2010, 21 (07) : 1486 - 1491
  • [28] Caspase 3a: new prognostic marker for diffuse large B-cell lymphoma in the rituximab era
    Provencio, Mariano
    Martin, Paloma
    Garcia, Vanesa
    Candia, Antonio
    Sanchez, Antonio C.
    Bellas, Carmen
    LEUKEMIA & LYMPHOMA, 2010, 51 (11) : 2021 - 2030
  • [29] Serum B-cell activating factor (BAFF) in diffuse large B-cell lymphoma: Its prognostic significance in the rituximab era
    Kim, Seok Jin
    Sung, Hwa Jung
    Choi, Chul Won
    Kim, In Sun
    Kim, Byung Soo
    Yoon, Soo-Young
    Won, Jong-Ho
    Kim, Jun Suk
    BLOOD, 2007, 110 (11) : 470A - 471A
  • [30] Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era
    Seo, Seyoung
    Hong, Jung Yong
    Yoon, Shinkyo
    Yoo, Changhoon
    Park, Ji Hyun
    Lee, Jung Bok
    Park, Chan-Sik
    Huh, Jooryung
    Lee, Yoonse
    Kim, Kyung Won
    Ryu, Jin-Sook
    Kim, Seok Jin
    Kim, Won Seog
    Yoon, Dok Hyun
    Suh, Cheolwon
    ONCOTARGET, 2016, 7 (47) : 76934 - 76943
12345